NCT01136733

A Study of E7080 Alone, and in Combination With Everolimus in Subjects With Unresectable Advanced or Metastatic Renal Cell Carcinoma Following One Prior Vascular Endothelial Growth Factor (VEGF)-Targeted Treatment

An Open-Label, Multicenter, Phase 1b/2 Study of E7080 Alone, and in Combination With Everolimus in Subjects With Unresectable Advanced or Metastatic Renal Cell Carcinoma Following One Prior VEGF-Targeted Treatment

• Status: Completed
• Phase: Phase 1 / Phase 2
• Study type: Interventional
• Enrollment: 173 (actual)
• Sponsor: Eisai Inc. · Industry
• Sex: All
• Age: 18 Years – 99 Years
• Healthy volunteers: Not accepted

Summary

This is an open-label, multicenter, Phase 1b/2 study of lenvatinib alone and in combination with everolimus in subjects with unresectable advanced or metastatic renal cell carcinoma following one prior VEGF-targeted treatment.

Conditions

• Metastatic Renal Cell Carcinoma

Interventions

Type	Name	Description
DRUG	Lenvatinib	taken orally, once a day
DRUG	Everolimus	taken orally, once a day

Timeline

• Start date: 2010-08-05
• Primary completion: 2014-06-13
• Completion: 2018-02-08
• First posted: 2010-06-03
• Last updated: 2019-02-27
• Results posted: 2019-02-27

Locations

37 sites across 5 countries: United States, Czechia, Poland, Spain, United Kingdom